129 related articles for article (PubMed ID: 27402614)
1. RET mutation and increased angiogenesis in medullary thyroid carcinomas.
Verrienti A; Tallini G; Colato C; Boichard A; Checquolo S; Pecce V; Sponziello M; Rosignolo F; de Biase D; Rhoden K; Casadei GP; Russo D; Visani M; Acquaviva G; Ferdeghini M; Filetti S; Durante C
Endocr Relat Cancer; 2016 Aug; 23(8):665-76. PubMed ID: 27402614
[TBL] [Abstract][Full Text] [Related]
2. Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma.
Gallel P; Pallares J; Dolcet X; Llobet D; Eritja N; Santacana M; Yeramian A; Palomar-Asenjo V; Lagarda H; Mauricio D; Encinas M; Matias-Guiu X
Hum Pathol; 2008 Jul; 39(7):994-1001. PubMed ID: 18508109
[TBL] [Abstract][Full Text] [Related]
3. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.
Kumarasamy VM; Shin YJ; White J; Sun D
BMC Cancer; 2015 Aug; 15():599. PubMed ID: 26307103
[TBL] [Abstract][Full Text] [Related]
4. VEGF, VEGFR3, and PDGFRB protein expression is influenced by RAS mutations in medullary thyroid carcinoma.
Mancikova V; Inglada-Pérez L; Curras-Freixes M; de Cubas AA; Gómez Á; Letón R; Kersten I; Leandro-García LJ; Comino-Méndez I; Apellaniz-Ruiz M; Sánchez L; Cascón A; Sastre-Marcos J; García JF; Rodríguez-Antona C; Robledo M
Thyroid; 2014 Aug; 24(8):1251-5. PubMed ID: 24754736
[TBL] [Abstract][Full Text] [Related]
5. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
Rodríguez-Antona C; Muñoz-Repeto I; Inglada-Pérez L; de Cubas AA; Mancikova V; Cañamero M; Maliszewska A; Gómez A; Letón R; Leandro-García LJ; Comino-Méndez I; Sanchez L; Alvarez-Escolá C; Aller J; Cascón A; Robledo M
Endocr Relat Cancer; 2013 Aug; 20(4):611-9. PubMed ID: 23780998
[TBL] [Abstract][Full Text] [Related]
6. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.
Rodríguez-Antona C; Pallares J; Montero-Conde C; Inglada-Pérez L; Castelblanco E; Landa I; Leskelä S; Leandro-García LJ; López-Jiménez E; Letón R; Cascón A; Lerma E; Martin MC; Carralero MC; Mauricio D; Cigudosa JC; Matias-Guiu X; Robledo M
Endocr Relat Cancer; 2010 Mar; 17(1):7-16. PubMed ID: 19776290
[TBL] [Abstract][Full Text] [Related]
7. Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in
Mancikova V; Montero-Conde C; Perales-Paton J; Fernandez A; Santacana M; Jodkowska K; Inglada-Pérez L; Castelblanco E; Borrego S; Encinas M; Matias-Guiu X; Fraga M; Robledo M
Clin Cancer Res; 2017 Mar; 23(5):1334-1345. PubMed ID: 27620278
[No Abstract] [Full Text] [Related]
8. mTOR activation in medullary thyroid carcinoma with RAS mutation.
Lyra J; Vinagre J; Batista R; Pinto V; Prazeres H; Rodrigues F; Eloy C; Sobrinho-Simões M; Soares P
Eur J Endocrinol; 2014 Nov; 171(5):633-40. PubMed ID: 25163725
[TBL] [Abstract][Full Text] [Related]
9. Search of the p.M918T Mutation in the RET Oncogene in Mexican Adult Patients with Medullary Thyroid Carcinoma.
Ruiz-Garcia E; Vidal-Millan S; Lopez-Yañez A; Torres JAP; Guadarrama-Orozco JA; Lino-Silva LS; Meneses-Garcia A; Astudillo-de la Vega H; Garcia MG
Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):218-222. PubMed ID: 28166591
[TBL] [Abstract][Full Text] [Related]
10. Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.
Lopergolo A; Perrone R; Tortoreto M; Doria F; Beretta GL; Zuco V; Freccero M; Borrello MG; Lanzi C; Richter SN; Zaffaroni N; Folini M
Oncotarget; 2016 Aug; 7(31):49649-49663. PubMed ID: 27351133
[TBL] [Abstract][Full Text] [Related]
11. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
[TBL] [Abstract][Full Text] [Related]
12. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
13. Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer.
Romei C; Ugolini C; Cosci B; Torregrossa L; Vivaldi A; Ciampi R; Tacito A; Basolo F; Materazzi G; Miccoli P; Vitti P; Pinchera A; Elisei R
Thyroid; 2012 May; 22(5):476-81. PubMed ID: 22404432
[TBL] [Abstract][Full Text] [Related]
14. Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display.
Musholt TJ; Hanack J; Brehm C; von Wasielewski R; Musholt PB
World J Surg; 2005 Apr; 29(4):472-82. PubMed ID: 15776290
[TBL] [Abstract][Full Text] [Related]
15. Expression of Tenascin C, EGFR, E-Cadherin, and TTF-1 in Medullary Thyroid Carcinoma and the Correlation with RET Mutation Status.
Steiner F; Hauser-Kronberger C; Rendl G; Rodrigues M; Pirich C
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409604
[TBL] [Abstract][Full Text] [Related]
16. Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer.
Sponziello M; Benvenuti S; Gentile A; Pecce V; Rosignolo F; Virzì AR; Milan M; Comoglio PM; Londin E; Fortina P; Barnabei A; Appetecchia M; Marandino F; Russo D; Filetti S; Durante C; Verrienti A
Hum Mutat; 2018 Mar; 39(3):371-377. PubMed ID: 29219214
[TBL] [Abstract][Full Text] [Related]
17. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation.
Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E
Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037
[TBL] [Abstract][Full Text] [Related]
18. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
[TBL] [Abstract][Full Text] [Related]
19. LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer.
Lindquist D; Alsina FC; Herdenberg C; Larsson C; Höppener J; Wang N; Paratcha G; Tarján M; Tot T; Henriksson R; Hedman H
Int J Oncol; 2018 Apr; 52(4):1189-1197. PubMed ID: 29436694
[TBL] [Abstract][Full Text] [Related]
20. Mice conditionally expressing RET(C618F) mutation display C cell hyperplasia and hyperganglionosis of the enteric nervous system.
Okamoto M; Yoshioka Y; Maeda K; Bito Y; Fukumoto T; Uesaka T; Enomoto H
Genesis; 2019 May; 57(5):e23292. PubMed ID: 30884088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]